

Synthesis of Multifunctional Organoboron Compounds by Copper-Catalyzed Enantioselective Reactions:

Author: Zeyu Huang

Persistent link: <http://hdl.handle.net/2345/bc-ir:107346>

This work is posted on [eScholarship@BC](#),
Boston College University Libraries.

Boston College Electronic Thesis or Dissertation, 2017

Copyright is held by the author, with all rights reserved, unless otherwise noted.

SYNTHESIS OF MULTIFUNCTIONAL ORGANOBORON COMPOUNDS BY COPPER-CATALYZED ENANTIOSELECTIVE REACTIONS

ZEYU HUANG

A thesis
submitted to the Faculty of
the Department of Chemistry
in partial fulfillment
of the requirements for the degree of
Master of Science

Boston College
Morrissey College of Arts and Sciences
Graduate School

May 2017


SYNTHESIS OF MULTIFUNCTIONAL ORGANOBORON COMPOUNDS BY COPPER-CATALYZED ENANTIOSELECTIVE REACTIONS

Zeyu Huang

Advisor: Professor Amir H. Hoveyda

Abstract

Chapter 1. We have developed a catalytic method for enantio- and S_N2' -selective allylic substitution of commercially available diborylmethane to trisubstituted allylic phosphates (pin = pinacolato). The transformations are catalyzed by NHC–Cu complexes (NHC = N-heterocyclic carbene). Products bearing quaternary stereogenic carbon centers are obtained in up to 86% yield (after oxidation), $>98:2$ S_N2'/S_N2 selectivity and 95:5 enantiomeric ratio (e.r.).



Chapter 2. We have developed a facile multicomponent catalytic process that begins with a chemo- and site-selective copper–hydride addition to allenyl-B(pin) followed by enantioselective conjugate addition of the resulting allylcopper intermediate to α,β -

unsaturated malonate, generating products that contain a stereogenic center and an easily functionalizable alkenyl-B(pin) group in up to 84% yield, >98:2 *E/Z* selectivity and 96:4 enantiomeric ratio. The transformations are catalyzed by chiral Cu complexes derived from commercially available bisphosphines and CuCl.




TABLE OF CONTENTS

| | |
|--|------------|
| Table of Contents | iii |
| Acknowledgements..... | v |
| 1.0 Chapter 1. Synthesis of Alkyl-B(pin) with an All-Carbon Quaternary Stereogenic Center by Catalytic Enantioselective Allylic Substitution with a Diborylmethane Reagent..... | 1 |
| 1.1 Introduction | 1 |
| 1.2 Background..... | 2 |
| 1.3 Identification of the Optimal Catalyst for Catalytic Enantioselective Allylic Substitution with a Diborylmethane Reagent..... | 4 |
| 1.4 Scope of Catalytic Enantioselective Allylic Substitution with a Diborylmethane Reagent..... | 7 |
| 1.5 Stereochemical Model for Catalytic Enantioselective Allylic Substitution with a Diborylmethane Reagent..... | 8 |
| 1.6 Application in Formal Synthesis of Bioactive Molecules..... | 9 |
| 1.7 Conclusions | 10 |
| 1.8 Experimental..... | 11 |
| 2.0 Chapter 2. Catalytic Enantioselective Multicomponent Allyl Conjugate Addition | 34 |
| 2.1 Introduction | 34 |
| 2.2 Background..... | 36 |
| 2.3 Optimization of Reaction Conditions for Catalytic Enantioselective Multicomponent Allyl Conjugate Addition | 39 |

| | | |
|------------|--|-----------|
| 2.4 | Scope of Catalytic Enantioselective Multicomponent Allyl Conjugate Addition..... | 42 |
| 2.5 | Functionalization of Products of Catalytic Enantioselective Multicomponent Allyl Conjugate Addition | 44 |
| 2.6 | Conclusions | 45 |
| 2.7 | Experimental..... | 45 |

ACKNOWLEDGMENTS

I would like to express my sincere appreciation to my advisor Prof. Amir H. Hoveyda for all of his supports, advices, and encouragements. Amir is passionate about thinking, talking and teaching about all kinds of chemistry. I was very lucky to join his group, and learned a lot not only in chemistry. I would also thank Prof. Marc L. Snapper and Prof. Masayuki Wasa for kindly accepting to serve as members of my thesis committee, spending time to read my thesis, and giving me valuable suggestions.

I would like to acknowledge my family. With their solid support, I can follow my heart and pursue what I want.

I would also thank my colleagues here. Ying Shi is my mentor, who helped me a lot academically. Dr. Fanke Meng contributed to improving my experimental techniques and understanding about chemistry. I would thank Dr. Youming, Yucheng, Jaehee, Farid and Ying for contributions on my thesis and for proof-reading. I would thank all other colleagues for all kinds of support. I really enjoyed working with them.

CHAPTER 1

SYNTHESIS OF ALKYL-B(PIN) WITH AN ALL-CARBON QUATERNARY STEREOGENIC CENTER BY CATALYTIC ENANTIOSELECTIVE ALLYLIC SUBSTITUTION WITH A DIBORYLMETHANE REAGENT

1.1 INTRODUCTION

One of the significant challenges in chemical synthesis is the development of efficient catalytic enantioselective reactions that furnish all-carbon quaternary stereogenic centers.¹ A general strategy for promoting such processes is the addition of carbon-based nucleophiles to electrophilic carbon sites. Copper-catalyzed enantioselective allylic substitution (EAS) is one of the most powerful carbon-carbon bond-forming reactions for the construction of stereogenic centers at the allylic position.² Significant progress has

(1) (a) *Quaternary Stereocenters: Challenges and Solutions for Organic Synthesis*; Christophers, J., Baro, A., Eds.; Wiley-VCH: Weinheim, 2006. (b) Douglas, C. J.; Overman, L. E. *Proc. Natl. Acad. Sci. U.S.A.* **2004**, *101*, 5363. (c) Cozzi, P. G.; Hilgraf, R.; Zimmermann, N. *Eur. J. Org. Chem.* **2007**, 5969.

(2) For representative reviews, see: (a) Alexakis, A.; Bäckvall, J. E.; Krause, N.; Pàmies, O.; Diéguez, M. *Chem. Rev.* **2008**, *108*, 2796-2823. (b) Harutyunyan, S. R.; den Hartog, T.; Geurts, K.; Minnaard, A. J.; Feringa, B. L. *Chem. Rev.* **2008**, *108*, 2824–2852.

been made in the enantioselective allylic substitution with organometallic reagents (for example, Mg-, Zn-, and Al-based nucleophiles).²

More recently, methodologies utilizing organoboron reagents, which are more functional group tolerant and widely available, such as diborylmethane, have been reported.³ We design the Cu-catalyzed enantioselective allylic substitution with di-B(pin)-methane to furnish compounds with all-carbon quaternary stereogenic centers as well as boronic ester and terminal olefin that can be easily transformed to other functional groups. We then applied this method to the synthesis of a bioactive molecule to highlight its utility.

1.2 BACKGROUND


Diborylmethane reagent **1.2** was first synthesized by Matteson and co-workers in 1982.⁴ Dichloromethane and lithium react with trimethylborate to generate the tetramethoxy diborylmethane. Then diborylmethane reagent **1.2** was formed by the addition of pinacol to tetramethoxy diborylmethane.

More recently, there has been reports on allylic substitutions with diborylmethane **1.2**. Cho and co-workers reported an NHC–Cu-catalyzed allylic substitution with diborylalkyl reagents (scheme 1.1).^{3a} Alkyl-B(pin) containing products are obtained in up to 86% yield and >99:1 S_N2':S_N2 selectivity.

(3) For examples of allylic substitution with di-B(pin)-methane, see: (a) Kim, J.; Park, S.; Park, J.; Cho, S. H. *Angew. Chem., Int. Ed.* **2016**, *55*, 1498–1501. (b) Zhang, Z.; Zhang, B.; Lu, X.; Liu, J.; Lu, X.; Xiao, B.; Fu, Y. *Org. Lett.* **2016**, *18*, 952–955. (c) Shi, Y.; Hoveyda A. H. *Angew. Chem., Int. Ed.* **2016**, *55*, 3455–3458. (d) Zhan, M.; Li, R. Z.; Mou, Z. D.; Cao, C. G.; Liu, J.; Chen, Y.; Niu, D. *ACS Catal.* **2016**, *6*, 3381–3386.


(4) Matteson, D. S.; Moody, R. J. *Organometallics* **1982**, *1*, 20–28.

Scheme 1.1 Cu-Catalyzed Allylic Substitution With Diborylalkyl Reagents




Fu and co-workers also reported a similar transformation (scheme 1.2).^{3b} Products are obtained in up to 88% yield and 98:2 S_N2':S_N2 selectivity. Products containing quaternary carbon centers are also generated with high efficiency.

Scheme 1.2 Cu-Catalyzed Allylic Substitution With Diboron Reagents



Hoveyda and co-workers reported the first enantioselective allylic substitution with diborylmethane **1.2** (scheme 1.3).^{3c} A wide range of aryl- and alkyl-substituted allylic phosphates can be transformed to products in up to 95% yield (after oxidation), 99:1 e.r. and 98:2 S_N2':S_N2 selectivity. The author also highlighted the method with the formal synthesis of rhopaloic acid A.


Scheme 1.3 Cu-Catalyzed Enantioselective Allylic Substitution With Diboron Reagents



Niu and co-workers also reported an Ir-catalyzed enantioselective allylic substitution with di-B(pin)-methane (scheme 1.4).^{3d} Products are obtained from aryl allylic carbonates

in high efficiency and enantiomeric ratio (up to 99% yield and 99:1 e.r.). The alkyl case reported is less efficient (one example with 24% NMR yield and N.D. e.r.).



Scheme 1.4 Ir-Catalyzed Enantioselective Allylic Substitution With Diboron Reagents



1.3 IDENTIFICATION OF THE OPTIMAL CATALYST FOR CATALYTIC ENANTIOSELECTIVE ALLYLIC SUBSTITUTION WITH A DIBORYLMETHANE REAGENT

We started our investigation from ligand screening for the methyleneboryl addition to *E*-allylic phosphate **1.10**. A variety of ligands, including different types of NHC-Ag complexes and phosphines are tested (table 1.1). The results indicate that phosphines deliver exclusively the undesired $\text{S}_{\text{N}}2$ products, while NHC-Ag complexes have comparatively better $\text{S}_{\text{N}}2'$ selectivity. By tuning the substitution patterns on the NHCs, different enantiomeric ratios can be achieved. NHC containing a mestiy group with a mono-phenyl backbone **N5** showed the highest enantioselectivity (84:16 e.r.) with 56% yield of **1.11** after oxidation (entry 5).

Table 1.1 Ligand Screening for the Enantioselective Allylic Substitution With Diborylmethane **1.2**




| Entry | Ligand | Conv. % ^b | S _N 2':S _N 2 ^c | Yield % ^d | e.r. ^e |
|-------|--------------------|----------------------|---|----------------------|-------------------|
| 1 | N1 | 88 | 93:7 | 74 | 78:22 |
| 2 | N2 | 75 | 83:17 | 38 | 75:25 |
| 3 | N3 | 71 | 5:95 | ND | NA |
| 4 | N4 | 62 | 58:42 | 33 | 74:26 |
| 5 | N5 | 72 | 93:7 | 56 | 84:16 |
| 6 | N6 | 79 | 93:7 | 69 | 81:19 |
| 7 | N7 | 65 | 39:61 | 25 | 68:32 |
| 8 | N8 | 74 | 61:39 | 36 | 44:56 |
| 9 | N9 | 84 | 48:52 | 33 | 20:80 |
| 10 | N10 | 72 | 98:2 | 60 | 38:62 |
| 11 | N11 | 73 | 98:2 | 52 | 36:64 |
| 12 | BINAP ^f | 52 | <2:>98 | ND | NA |
| 13 | dppp ^f | 63 | <2:>98 | ND | NA |
| 14 | SIMes ^f | 24 | <2:>98 | ND | NA |

^a Reactions were performed under N₂ atmosphere. ^{b,c} Determined by analysis of 400 MHz ¹H NMR of unpurified mixtures. ^d Isolated yield after oxidation. ^e Determined by HPLC analysis. ^f 5.5 mol % of ligand used.

We then investigated a variety of ligands for the the addition to Z-allylic phosphate **1.12**, since the allylic substitution would generate the same product. As shown in table 1.2, to our delight, complexes with 3,6-substituted N-Aryl group would lead to higher enantioselectivity (90:10 e.r. and 92:8 e.r., entry 7,8), although ligands with other substituted patterns afford lower e.r. Among them, **N12** promotes an efficient reaction with 98:2 S_N2':S_N2 selectivity, 80% yield and 92:8 e.r.

Table 1.2 Ligand Screening Enantioselective Allylic Substitution With Diboron Reagents





| Entry | Ligand | Conv. % ^b | S _N 2':S _N 2 ^c | Yield % ^d | e.r. ^e |
|----------------|------------|----------------------|---|----------------------|-------------------|
| 1 | N1 | 68 | 67:33 | 25 | 67:33 |
| 2 | N5 | 67 | 81:19 | 38 | 62:38 |
| 3 | N7 | 70 | 25:75 | 13 | 64: 36 |
| 4 | N8 | 80 | 3:97 | ND | ND |
| 5 | N9 | 72 | 19:81 | 12 | 54:46 |
| 6 | N10 | 70 | 57:43 | 36 | 76:24 |
| 7 | N11 | 86 | 93:7 | 76 | 90:10 |
| 8 | N12 | 98 | 98:2 | 80 | 92:8 |
| 9 ^f | N11 | <5 | NA | NA | NA |

^a Reactions were performed under N₂ atmosphere. ^{b,c} Determined by analysis of 400 MHz ¹H NMR of unpurified mixtures. ^d Isolated yield after oxidation. ^e Determined by HPLC analysis. ^f Without CuCl.


1.4 SCOPE OF CATALYTIC ENANTIOSELECTIVE ALLYLIC SUBSTITUTION WITH A DIBORYLMETHANE REAGENT

With the optimized conditions in hand, we explored the scope of the enantioselective allylic substitution with diborylmethane **1.2**. As shown in scheme 1.5, halogen-containing substrates are well tolerated (**1.11b**, **1.11c**, **1.11g**). Allylic phosphates bearing electron-rich and electron-poor arenes are also suitable substrates (**1.11d**, **1.11e**). Sterically-demanding substrate with o-OMe substituent **1.11f** works well, with a slightly lower efficiency (79% yield and 95:5 e.r.). Alkyl allylic phosphate **1.11h** also works well but with a moderate enantiomeric ratio (84:16 e.r.), probably due to the difficulty in differentiating an alkyl group with a methyl group. Additions to most of these substrates afford excellent S_N2' selectivities ($\geq 98:2$), except for electron-deficient p-CF₃ containing **1.11d** (85:15), probably because the higher reactivity makes the energetic difference between the desired pathway and the background reaction that leads to S_N2 product is smaller.


Scheme 1.5 Scope of Enantioselective Allylic Substitution With Diboron Reagents




1.11
 88% conv., 80% yield,
 98:2 S_N2':S_N2, 92:8 e.r.




1.11b
 90% conv., 78% yield,
 98:2 S_N2':S_N2, 95:5 e.r.




1.11c
 83% conv., 69% yield
 98:2 S_N2':S_N2, 94.5:5.5 e.r.




1.11d
 96% conv., 70% yield,
 85:15 S_N2':S_N2, 95:5 e.r.




1.11e
 70% conv., 67% yield,
 >98:2 S_N2':S_N2, 94:6 e.r.



1.11f^{a,b,c}
 86% conv., 79% yield,
 98:2 S_N2':S_N2, 95:5 e.r.



1.11g^{a,b,d}
 82% conv., 67% yield,
 98:2 S_N2':S_N2, 91:9 e.r.



1.11h^b
 94% conv., 86% yield,
 98:2 S_N2':S_N2, 84:16 e.r.


^a 7.5 mol % CuCl, 4.1 mol % ligand used. ^b **N11** used instead of **N12**. ^c 96 h instead of 24 h. ^d 48 h instead of 24 h. ^e Isolated yield of pure S_N2' product.

1.5 STEREOCHEMICAL MODEL FOR CATALYTIC ENANTIOSELECTIVE ALLYLIC SUBSTITUTION WITH A DIBORYLMETHANE REAGENT

We then envisioned a stereochemical model for the enantioselective allylic substitution which accounts for the observed enantioselectivity. As shown in scheme 1.6,

the extended bulky Ar group on the NHC would push the B(pin) moiety away from itself, which favors pathway a. The difference between the two substituents with B(pin) (Ph vs Me) accounts for the generation of the major enantiomer **1.13**. Mechanistic rationale accounting for the better performance of *Z* vs *E* substrates requires further study.

Scheme 1.6 Stereochemical Model for Enantioselective Allylic Substitution




1.6 APPLICATION IN FORMAL SYNTHESIS OF BIOACTIVE MOLECULES

The terminal olefin and pinacolboronic ester group presented in the products of enantioselective allylic substitution provide a potential for conversion to a variety of valuable intermediates in the synthesis of natural products and pharmaceuticals. For

example, oxidation of compound **1.11** with ozone and hydrogen peroxide produced (*R*)- α -methyltropic acid **1.15**,⁵ which is a key intermediate for the synthesis of (*R*)-Atromepine, a drug treating heart rhythm disease (scheme 1.7).⁶ Our method generates the desired compound **1.11** in higher yield and enantiomeric ratio than previous reports.⁵

Scheme 1.7 Formal Synthesis of (*R*)-Atromepine



1.7 CONCLUSION

We have developed a catalytic method for enantio- and S_N2' -selective allylic substitution of commercially available diborylmethane to trisubstituted allylic phosphates. The transformations are catalyzed by NHC–Cu complexes. Products bearing quaternary stereogenic carbon centers are obtained in up to 86% yield (after oxidation), >98:2 S_N2' : S_N2 selectivity and 95:5 enantiomeric ratio. We applied this method in the formal synthesis of bioactive molecule (*R*)-Atromepine. Further studies on expanding substrate scope, mechanistic studies, functionalization of products and application towards the synthesis of valuable compounds are in progress.

(5) Zhang, Q.; Zhu, S.; Cai, Y.; Wang, L.; Zhang, Q. *Sci China Chem*, **2010**, 53, 1899-1906.

(6) Melone G.; Vecchi A.; Pagani G.; Testa E. *J. Org. Chem.* **1960**, 25, 859–861.

1.8 EXPERIMENTAL

General

Infrared (IR) spectra were recorded on a Bruker FT-IR Alpha (ATR mode) spectrophotometer, ν_{max} in cm^{-1} . Bands are characterized as broad (br), strong (s), medium (m), and weak (w). ^1H NMR spectra were recorded on a Varian Unity INOVA 400 (400 MHz) spectrometer. Chemical shifts are reported in ppm from tetramethylsilane with the solvent resonance as the internal standard (CDCl_3 : δ 7.26 ppm). Data are reported as follows: chemical shift, integration, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br s = broad singlet, m = multiplet, app. = apparent), and coupling constant (Hz). ^{13}C NMR spectra were recorded on a Varian Unity INOVA 400 (100 MHz) spectrometer with complete proton decoupling. Chemical shifts are reported in ppm from tetramethylsilane with the solvent resonance as the internal standard (CDCl_3 : δ 77.00 ppm). High-resolution mass spectrometry was performed on a JEOL AccuTOF DART (positive mode) at the Mass Spectrometry Facility, Boston College. Enantiomer ratios were determined by high-performance liquid chromatography (HPLC) with a Shimadzu chromatograph (Chiral Technologies Chiralpak AZ-H (5.0×250 mm), Chiralpak OD-H (5.0×250 mm)) in comparison with authentic racemic materials. Specific rotations were measured on a Rudolph Research Analytical Autopol IV polarimeter.

Unless otherwise noted, all reactions were carried out with distilled and degassed solvents under an atmosphere of dry N_2 in oven- (135°C) or flame-dried glassware with standard dry box or vacuum-line techniques. Solvents were purified under a positive pressure of dry argon by a modified Innovative Technologies purification system: toluene, benzene and hexanes were purified through a copper oxide and alumina column; CH_2Cl_2

and Et₂O were purged with Ar and purified by passage through two alumina columns. Tetrahydrofuran (Aldrich Chemical Co.) was purified by distillation from sodium benzophenone ketyl immediately prior to use unless otherwise specified. All work-up and purification procedures were carried out with reagent grade solvents (purchased from Fisher Scientific) in air.

Reagents and Ligands

Allylic phosphates: prepared according to previously reported methods.^{7,8}

Bis[(pinacolato)boryl]methane (1.2): prepared according to previously reported methods.⁹

Copper (I) chloride: purchased from Strem Chemicals Inc. and used as received.

Diethyl chlorophosphate: purchased from Aldrich and used as received.

NHC–Ag complexes: prepared following previously reported methods.¹⁰

Sodium perborate tetrahydrate: purchased from Aldrich and used as received.

Sodium methoxide: purchased from Strem Chemicals Inc. and used as received.

Triethylamine: purchased from Fisher Scientific, Inc. and distilled over CaH₂ prior to use.

Representative Procedure for Cu(I)-Catalyzed Enantioselective Allylic Substitution

with Diboron Reagents:

An oven-dried 1 dram vial equipped with a stir bar was charged with NHC-Ag

(7) Jung, B.; Hoveyda, A. H. *J. Am. Chem. Soc.*, **2012**, *134*, 1490–1493.

(8) Takeda, M.; Takatsu, K.; Shintani, R.; Hayashi, T. *J. Org. Chem.*, **2014**, *79*, 2354–2367.

(9) Sun, C.; Potter, B.; Morken, J. P. *J. Am. Chem. Soc.* **2014**, *136*, 6534–6537.

(10) (a) May, T. L.; Brown, M. K.; Hoveyda, A. H. *Angew. Chem., Int. Ed.* **2008**, *47*, 7358–7362. (b) Akiyama, K.; Gao, F.; Hoveyda, A. H. *Angew. Chem. Int. Ed.* **2010**, *49*, 419–423.

complex **N12** (4.0 mg, 2.75 μ mol) and CuCl (0.5 mg, 5 μ mol) in a nitrogen-filled glove box. Freshly distilled THF (0.8 mL) was added to the vial and the mixture was allowed to stir at 22 °C for 2 h. After that, NaOMe (6.5 mg, 120 μ mol) was added and the vial was sealed with a cap (phenolic open top cap with a red PFTE/white silicon septum) and electrical tape, and removed from the glove box. The solution of allylic phosphate (28.4 mg, 0.10 mmol) and diborylmethane **1.2** (40.2 mg, 0.15 mmol) in THF (0.3 mL) was added to the reaction mixture through a plastic syringe and the resulting mixture was allowed to stir at 22 °C for 24 h.


The mixture was passed through a short plug of silica gel and eluted with Et₂O. The organic layer was concentrated *in vacuo*, and then NaBO₃•4H₂O (46.2 mg, 0.30 mmol), THF (1 mL) and H₂O (1 mL) was added to the same vessel. The mixture was allowed to stir at 22 °C for 3 h. The mixture was extracted with Et₂O and concentrated to give colorless oil, which was purified by silica gel chromatography to afford the desired product as colorless oil.

(S)-2-Methyl-2-phenylbut-3-en-1-ol (1.11):

¹H NMR (CDCl₃, 400 MHz): δ 7.36–7.24 (5H, m), 6.08 (1H, dd, J = 17.6, 10.8 Hz), 5.28 (1H, dd, J = 10.8, 1.2 Hz), 5.16 (1H, dd, J = 17.6, 1.2 Hz), 3.80 (2H, d, J = 6.4 Hz), 1.44 (3H, s), 1.35 (1H, br s). The ¹H NMR matches previous report.¹¹ Specific rotation: $[\alpha]_D^{20}$ 16.3 (c 1.0, EtOH) for an enantiomerically enriched sample of 92:8 e.r., and absolute configuration assigned as *S*.⁵

(11) Ngai, M. Y.; Skucas, E.; Krische, M. J. *Org. Lett.* **2008**, *10*, 2705.

Enantiomeric purity was determined by HPLC analysis in comparison with authentic racemic material; Chiralpak AZ–H column, 99.5:0.5 hexanes/*i*PrOH, 1.0 mL/min, 220 nm.




| Peak # | Time (min) | Area (%) | Peak # | Time (min) | Area (%) |
|--------|------------|----------|--------|------------|----------|
| 1 | 102.487 | 50.276 | 1 | 77.702 | 92.769 |
| 2 | 152.128 | 49.724 | 2 | 111.390 | 7.231 |

(S)-2-(3-Bromophenyl)-2-methylbut-3-en-1-ol (1.11b):

IR (neat): 3392 (br), 2969 (m), 2932 (m), 2875 (m), 1592 (m), 1562 (s), 1474 (s), 1416 (s), 1071 (s), 1041 (s), 997 (s), 921 (s), 783 (s), 747 (s), 699 (s) cm^{-1} ; ^1H NMR (CDCl_3 , 400 MHz): δ 7.47 (1H, t, $J = 1.6$ Hz), 7.37-7.34 (1H, m), 7.29-7.24 (1H, m), 7.19 (1H, t, $J = 4.0$ Hz), 6.01 (1H, ddd, $J = 17.6, 10.8, 1.2$ Hz), 5.28 (1H, dd, $J = 10.8, 1.2$ Hz), 5.14 (1H, d, $J = 17.6$ Hz), 3.75 (2H, d, $J = 1.6$ Hz), 1.39-1.38 (4H, m); ^{13}C NMR (CDCl_3 , 100 MHz): δ 147.1, 142.8, 130.2, 129.9, 129.6, 125.6, 122.7, 115.2, 69.7, 47.0, 22.6; HRMS (ESI^+): Calcd for $\text{C}_{11}\text{H}_{12}\text{Br}$ $[\text{M}+\text{H}-\text{H}_2\text{O}]^+$: 223.0112; Found: 223.0132. Specific rotation: $[\alpha]_{\text{D}}^{20}$ 9.8 (c 1.0, CHCl_3) for an enantiomerically enriched sample of 95:5 e.r.

Enantiomeric purity was determined by HPLC analysis in comparison with authentic racemic material; Chiralpak OD–H column, 99.5:0.5 hexanes/*i*PrOH, 0.5 mL/min, 220 nm.




| Peak # | Time (min) | Area (%) | Peak # | Time (min) | Area (%) |
|--------|------------|----------|--------|------------|----------|
| 1 | 126.803 | 51.884 | 1 | 118.804 | 4.924 |
| 2 | 137.815 | 48.116 | 2 | 126.492 | 95.076 |

(*S*)-2-(3-Chlorophenyl)-2-methylbut-3-en-1-ol (1.11c):


¹H NMR (CDCl₃, 400 MHz): δ 7.34-7.33 (1H, m), 7.27-7.22 (4H, m), 6.04 (1H, dd, *J* = 17.6, 10.8 Hz), 5.29 (1H, dd, *J* = 10.0, 1.2 Hz), 5.16 (1H, dd, *J* = 17.6, 1.2 Hz), 3.78 (2H, d, *J* = 6.8 Hz), 1.47-1.35 (4H, m); ¹³C NMR (CDCl₃, 100 MHz): δ 146.8, 142.8, 134.4, 129.6, 127.4, 126.7, 125.1, 115.2, 69.7, 47.0, 22.6;

Enantiomeric purity was determined by HPLC analysis in comparison with authentic racemic material; Chiralpak AZ–H column, 99.0:1.0 hexanes/*i*PrOH, 0.5 mL/min, 220 nm.



<Peak Table>

| Peak# | Ret. Time | Area | Height | Conc. | Unit | Mark | Name |
|-------|-----------|-----------|---------|--------|------|------|------|
| 1 | 51.852 | 98053732 | 1345448 | 49.853 | | M | |
| 2 | 69.645 | 98630687 | 864933 | 50.147 | | M | |
| Total | | 196684419 | 2210381 | | | | |



<Peak Table>

| Peak# | Ret. Time | Area | Height | Conc. | Unit | Mark | Name |
|-------|-----------|----------|---------|--------|------|------|------|
| 1 | 51.050 | 66417653 | 991775 | 94.527 | | M | |
| 2 | 70.920 | 3845228 | 49871 | 5.473 | | M | |
| Total | | 70262881 | 1041646 | | | | |

| Peak # | Time (min) | Area (%) | Peak # | Time (min) | Area (%) |
|--------|------------|----------|--------|------------|----------|
| 1 | 51.852 | 49.853 | 1 | 51.050 | 94.527 |
| 2 | 69.645 | 50.147 | 2 | 70.920 | 5.473 |

(S)-2-Methyl-2-(4-(trifluoromethyl)phenyl)but-3-en-1-ol (1.11d):

IR (neat): 3380 (br), 2970 (w), 2936 (w), 1618 (w), 1412 (w), 1372 (s), 1165 (s), 1123 (s), 1067 (s), 1016 (s), 922 (s), 838 (m), 706 (w), 606 (w) cm^{-1} ; ^1H NMR (CDCl_3 , 400 MHz): δ 7.57 (2H, d, $J = 7.6$ Hz), 7.47 (2H, d, $J = 7.6$ Hz), 6.04 (1H, dd, $J = 18.0, 10.4$ Hz), 5.30 (1H, d, $J = 10.8$ Hz), 5.14 (1H, d, $J = 17.6$ Hz), 3.80 (2H, s), 1.43 (3H, s), 1.40 (1H, br); ^{13}C NMR (CDCl_3 , 100 MHz): δ 148.8 ($J = 2$ Hz), 142.7, 128.7 (q, $J = 32$ Hz), 127.4, 125.5-125.2 (m), 122.8, 120.1, 115.5, 69.6, 47.1, 22.7; HRMS (ESI^+): Calcd for $\text{C}_{12}\text{H}_{12}\text{F}_3$ $[\text{M}+\text{H}-\text{H}_2\text{O}]^+$: 213.0891; Found: 213.0884. Specific rotation: $[\alpha]_{\text{D}}^{20}$ 7.4 (c 1.0, CHCl_3) for an enantiomerically enriched sample of 95:5 e.r.


Enantiomeric purity was determined by HPLC analysis in comparison with authentic racemic material; Chiralpak AZ-H column, 99.5:0.5 hexanes/*i*PrOH, 0.5 mL/min, 220 nm. Retention time: 66.49 min (major), 73.47 (minor).

(S)-2-Methyl-2-(naphthalen-2-yl)but-3-en-1-ol (1.11e):

^1H NMR (CDCl_3 , 500 MHz): δ 7.83-7.79 (4H, m), 7.51-7.46 (3H, m), 6.17 (1H, dd, $J = 18.0, 11.0$ Hz), 5.33 (1H, d, $J = 11.0$ Hz), 5.20 (1H, d, $J = 17.5$ Hz), 3.90 (2H, s), 1.54


(3H, s); ^{13}C NMR (CDCl_3 , 100 MHz): δ 143.5, 141.8, 133.4, 132.1, 128.1, 128.0, 127.4, 126.1, 125.8, 125.6, 125.3, 114.9, 69.9, 47.2, 22.7.

Enantiomeric purity was determined by HPLC analysis in comparison with authentic racemic material; Chiralpak AZ-H column, 99.0:1.0 hexanes/*i*PrOH, 0.5 mL/min, 220 nm.



<Peak Table>

| Peak# | Ret. Time | Area | Height | Conc. | Unit | Mark | Name |
|-------|-----------|----------|--------|--------|------|------|------|
| 1 | 73.261 | 23793941 | 287528 | 49.915 | | M | |
| 2 | 86.304 | 23874689 | 243798 | 50.085 | | M | |
| Total | | 47668630 | 531326 | | | | |



<Peak Table>


| Peak# | Ret. Time | Area | Height | Conc. | Unit | Mark | Name |
|-------|-----------|-----------|---------|--------|------|------|------|
| 1 | 70.831 | 145631356 | 1540613 | 94.074 | | M | |
| 2 | 84.634 | 9173620 | 99277 | 5.926 | | M | |
| Total | | 154804976 | 1639890 | | | | |

| Peak # | Time (min) | Area (%) | Peak # | Time (min) | Area (%) |
|--------|------------|----------|--------|------------|----------|
| 1 | 73.261 | 49.915 | 1 | 70.831 | 94.074 |
| 2 | 86.304 | 50.085 | 2 | 84.634 | 5.926 |

(S)-2-(2-Methoxyphenyl)-2-methylbut-3-en-1-ol (1.11f):

IR (neat): 3421 (br), 2936 (w), 2881 (w), 1598 (w), 1498 (s), 1462 (m), 1434 (m), 1240 (s), 1027 (s), 914 (m), 753 (s), 700 (w) cm^{-1} ; ^1H NMR (CDCl_3 , 400 MHz): δ 7.29 (1H, dd, J = 8.0, 1.6 Hz), 7.24-7.20 (1H, m), 6.94-6.88 (2H, m), 6.20 (1H, dd, J = 18.0, 10.4 Hz), 5.16 (1H, dd, J = 10.8, 1.2 Hz), 5.03 (1H, dd, J = 18.0, 1.2 Hz), 3.98-3.93 (1H, m), 3.89-3.84 (1H, m), 3.80 (3H, s), 1.44 (3H, s); ^{13}C NMR (CDCl_3 , 100 MHz): δ 157.9, 144.0, 132.3, 129.1, 128.0, 120.7, 113.2, 111.9, 68.5, 55.2, 47.0, 21.7; HRMS (ESI^+): Calcd for $\text{C}_{12}\text{H}_{16}\text{O}_2$ $[\text{M}+\text{H}]^+$: 193.1229; Found: 193.123. Specific rotation: $[\alpha]_{\text{D}}^{20}$ 14.4 (c 0.5, CHCl_3) for an enantiomerically enriched sample of 95:5 e.r.

Enantiomeric purity was determined by HPLC analysis in comparison with authentic racemic material; Chiralpak OD–H column, 99.5:0.5 hexanes/*i*PrOH, 0.5 mL/min, 220 nm.




| Peak # | Time (min) | Area (%) | Peak # | Time (min) | Area (%) |
|--------|------------|----------|--------|------------|----------|
| 1 | 81.429 | 49.825 | 1 | 129.295 | 5.136 |
| 2 | 93.372 | 50.175 | 2 | 148.027 | 94.864 |

(S)-2-(2-Fluorophenyl)-2-methylbut-3-en-1-ol (1.11g):


IR (neat): 3431 (br), 2926 (m), 2855 (w), 1598 (w), 1488 (m), 1447 (m), 1217 (m), 1039 (s), 919 (w), 809 (s), 756 (s) cm^{-1} ; ^1H NMR (CDCl_3 , 500 MHz): δ 7.37-7.34 (1H, m), 7.26-7.22 (1H, m), 7.12-7.09 (1H, m), 7.05-7.00 (1H, m), 6.14 (1H, dd, $J = 17.5, 11.0$ Hz), 5.26 (1H, d, $J = 10.5$ Hz), 5.09 (1H, d, $J = 18.0$ Hz), 3.89 (1H, d, $J = 4.5$ Hz), 1.48 (3H, s);

Enantiomeric purity was determined by HPLC analysis in comparison with authentic racemic material; Chiralpak AZ–H column, 99.5:0.5 hexanes/*i*PrOH, 0.5 mL/min, 220 nm.



<Peak Table>

| Peak# | Ret. Time | Area | Height | Conc. | Unit | Mark |
|-------|-----------|---------|--------|--------|------|------|
| 1 | 52.677 | 4559757 | 69541 | 48.825 | | M |
| 2 | 66.453 | 4779296 | 52490 | 51.175 | | M |
| Total | | 9339054 | 122032 | | | |



<Peak Table>


| Peak# | Ret. Time | Area | Height | Conc. | Unit | Mark |
|-------|-----------|---------|--------|--------|------|------|
| 1 | 53.195 | 4487426 | 68180 | 91.974 | | M |
| 2 | 68.077 | 391594 | 5712 | 8.026 | | M |
| Total | | 4879019 | 73892 | | | |

| Peak # | Time (min) | Area (%) | Peak # | Time (min) | Area (%) |
|--------|------------|----------|--------|------------|----------|
| 1 | 52.677 | 48.825 | 1 | 53.195 | 91.974 |
| 2 | 66.453 | 51.175 | 2 | 68.077 | 8.026 |

(R)-2-(((tert-butyldimethylsilyl)oxy)methyl)-2-methylbut-3-en-1-ol (1.11h):

IR (neat): 2927 (m), 1723 (s), 1470 (m), 1268 (s), 1096 (s), 1027 (m), 837 (s), 776 (m), 709 (s) cm^{-1} ; ^1H NMR (CDCl_3 , 400 MHz): δ 5.81 (1H, dd, $J = 17.6, 10.8$ Hz), 5.13 (1H, dd, $J = 6.8, 1.2$ Hz), 5.09 (1H, dd, $J = 12.8, 1.2$ Hz), 3.63-3.45 (4H, m), 2.52 (1H, br), 1.00 (3H, s), 0.89 (9H, s), 0.04 (6H, s); ^{13}C NMR (CDCl_3 , 100 MHz): δ 141.3, 114.5, 70.4, 69.8, 43.0, 33.9, 29.7, 25.8, 18.4, 18.1, -5.7, -5.7; HRMS (ESI^+): Calcd for $\text{C}_{12}\text{H}_{15}\text{OSi}$ $[\text{M}+\text{H}-\text{H}_2\text{O}]^+$: 213.1675; Found: 213.168. Specific rotation: $[\alpha]_{\text{D}}^{20}$ 0.2 (c 1.0, CHCl_3) for an enantiomerically enriched sample of 84:16 e.r.


Enantiomeric purity was determined by HPLC analysis in comparison with authentic racemic material of benzoate derivatives; Chiralpak OD-H column, 100% hexanes, 0.2 mL/min, 220 nm.



<Peak Table>

Detector A Channel 2 220nm

| Peak# | Ret. Time | Area | Height | Conc. | Unit | Mark |
|-------|-----------|-----------|---------|--------|------|------|
| 1 | 38.643 | 52778054 | 979613 | 47.222 | | M |
| 2 | 40.337 | 58987079 | 856206 | 52.778 | | V M |
| Total | | 111765133 | 1835820 | | | |






<Peak Table>

Detector A Channel 2 220nm


| Peak# | Ret. Time | Area | Height | Conc. | Unit | Mark |
|-------|-----------|----------|---------|--------|------|------|
| 1 | 36.267 | 8858598 | 214575 | 15.701 | | M |
| 2 | 37.567 | 47563137 | 922089 | 84.299 | | V M |
| Total | | 56421734 | 1136664 | | | |


| Peak # | Time (min) | Area (%) | Peak # | Time (min) | Area (%) |
|--------|------------|----------|--------|------------|----------|
| 1 | 38.643 | 47.222 | 1 | 36.267 | 15.701 |
| 2 | 40.337 | 52.778 | 2 | 37.567 | 84.299 |







1.11b







1.11c







1.11c







1.11d







1.11d







1.11e







1.11e







1.11f.







1.11f.







1.11g






1.11h





1.11h



CHAPTER 2

CATALYTIC ENANTIOSELECTIVE MULTICOMPONENT ALLYL CONJUGATE ADDITION


2.1 INTRODUCTION

Catalytic enantioselective conjugate additions are very important transformations in organic synthesis.¹² Many kinds of catalytic reactions are reported to transfer a variety of functional groups, such as aryl, alkenyl and alkyl groups, to the stereogenic center with high efficiency and enantioselectivity. Among these reports, catalytic enantioselective conjugate additions of allyl groups to α,β -unsaturated carbonyl compounds are rare. One challenging problem would be the undesired competitive background reactions caused by the ligand-free allylmetal species due to their high nucleophilicity. Another issue might be that stable π -allyl metal complexes do not easy to undergo reductive elimination.

(12) For reviews on catalytic enantioselective conjugate addition, see: (a) Harutyunyan, S. R.; den Hartog, T.; Geurts, K.; Minnaard, A. J.; Feringa, B. L. *Chem. Rev.* **2008**, *108*, 2824–2852. (b) Jerphagnon, T.; Pizzuti, M. G.; Minnaard, A. J.; Feringa, B. L. *Chem. Soc. Rev.* **2009**, *38*, 1039–1075. (c) Cordova, A. *Catalytic Asymmetric Conjugate Reactions*; Wiley-VCH: Weinheim, **2010**. (d) Ji, J.-X.; Chan, A. S. C. *Catalytic Asymmetric Synthesis* (Ed.: I. Ojima); Wiley, Hoboken, **2010**, pp. 439–495.

Hoveyda group has recently reported catalytic enantioselective conjugate additions of propargyl and allyl groups.¹³ We designed a catalytic multicomponent process (scheme 2.1) that begins with the formation of Cu-H species **II** from Cu^I alkoxide **I**, followed by Cu-H addition to allenyl-B(pin) to generate allylcopper intermediate **III**. The conjugate addition of allylcopper intermediate **III** to α,β -unsaturated malonate **IV** gives the intermediate **V**, followed by ligand exchange to regenerate Cu^I alkoxide **I** and afford the desired conjugate addition product **VII**.

Scheme 2.1 Catalytic Cycle for Cu-Catalyzed Multicomponent 1,4-Conjugate Addition




(13) (a) Meng, F.; Li, X.; Torker, S.; Shi, Y.; Shen, X.; Hoveyda, A. H. *Nature*, **2016**, 537, 387–393.
 (b) Li, X.; Meng, F.; Torker, S.; Shi, Y.; Hoveyda, A. H. *Angew. Chem., Int. Ed.* **2016**, 55, 9997–10002.

A common problem for multicomponent reactions would be chemoselectivity issues in this process. For example, Cu alkoxide **I** can react with allenyl-B(pin) **2.2** to generate allenylcopper, which could participate in conjugate addition as well. Cu-H complex **II** can also directly add to α,β -unsaturated malonate **IV** to give reduction product. Besides all the aforementioned issues, allylcopper intermediate **III** could isomerize, which would generate linear & branched allylcopper, as well as *E*- & *Z*-isomers in a non-selective fashion. We hope to develop an efficient and enantioselective conjugate addition where side process can be minimized.

2.2 BACKGROUND

As for previous reports on enantioselective allyl conjugate addition, Morken and co-workers reported Ni-catalyzed enantioselective addition of allyl-B(pin) to dienone. (Scheme 2.2).¹⁴ The reaction is very effective with dialkylidene ketones and favors the allylation of the benzyldiene site in nonsymmetric substrates. The authors propose a mechanism involving an oxidative π -allyl formation and a 3,3'-reductive elimination process.


Scheme 2.2 Ni-Catalyzed Enantioselective Allyl Conjugate Addition



(14) Sieber, J. D.; Morken, J. P. *J. Am. Chem. Soc.* **2008**, *130*, 4978–4983.


In 2008, the Snapper group reported catalytic enantioselective Hosomi–Sakurai conjugate allylation of cyclic unsaturated ketoesters (Scheme 2.3).¹⁵ Conjugate addition products can be generated in up to 78% yield and >98:2 e.r. with a bisoxazole-Cu complex.

Scheme 2.3 Catalytic Enantioselective Hosomi-Sakurai Allyl Conjugate Additions



In 2011, Shibasaki and co-workers reported the enantioselective conjugate addition of allyl cyanide to α,β -unsaturated thioamides **2.9** (Scheme 2.4).¹⁶ Product **2.10** is obtained in 87% yield and 98.5:1.5 e.r.

Scheme 2.4 Cu-Catalyzed Enantioselective Conjugate Addition of Cyano-containing Allyl Group



In 2011, Feng and co-workers reported catalytic enantioselective conjugate allylation to coumarins (Scheme 2.5).¹⁷ They employed a dual activation strategy by using N,N'-dioxide- $\text{Yb}(\text{OTf})_3$ to activate coumarin **2.11**, and using $(\text{CuOTf})_2\cdot\text{C}_7\text{H}_8$ to


(15) Shizuka, M.; Snapper, M. L. *Angew. Chem., Int. Ed.* **2008**, *47*, 5049–5051.

(16) Yanagida, Y.; Yazaki, R.; Kumagai, N.; Shibasaki, M. *Angew. Chem., Int. Ed.* **2011**, *50*, 7910–7914.

(17) Kuang, Y.; Liu, X.; Chang, L.; Wang, M.; Lin, L.; Feng, X. *Org. Lett.* **2011**, *13*, 3814–3817.


activate tetraallyltin **2.12** by transmetalation. Products are obtained in up to 99% yield, >19:1 d.r. and 96.5:3.5 e.r. under mild conditions.

Scheme 2.5 Catalytic Enantioselective Conjugate Allyl Addition to Coumarins



In 2016, Hoveyda and co-workers reported catalytic enantioselective 1,6-conjugate additions of allyl-type nucleophiles promoted by NHC–Cu complexes (Scheme 2.6).^{13a} Propargyl and allyl 1,6-addition products are formed in high efficiencies, diastereo- and enantioselectivities. The author proposed that the transformations proceed through an unprecedented Cu-catalyzed 3,3'-reductive elimination.


Scheme 2.6 Catalytic Enantioselective 1,6-Conjugate Addition of Propargyl and Allyl Groups



In the same year, Hoveyda and co-workers reported multicomponent catalytic enantioselective conjugate additions of (pin)B-substituted allylcopper to α,β -unsaturated

malonate (Scheme 2.7).^{13b} Desired products are obtained in up to 83% yield and 98:2 enantiomeric ratio.



Scheme 2.7 Catalytic Enantioselective Conjugate Addition of (pin)B-Substituted Allylcopper Compounds




2.3 OPTIMIZATION OF REACTION CONDITIONS FOR CATALYTIC ENANTIOSELECTIVE MULTICOMPONENT ALLYL CONJUGATE ADDITION

We started our investigation with ligand screening for the multicomponent allyl conjugate addition. A variety of ligands were tested, as shown in table 2.1. One major byproduct is malonate **2.27** derived from direct reduction of α,β -unsaturated malonate **2.25**. Reactions catalyzed by some bisphosphine ligands, such as **L3**, **L4**, **L6**, **L7**, **L10** and **L11**, can generate product efficiently with moderate chemoselectivity and enantiomeric ratio. Among them, **L11** (*R*)-DTBM-SEGPHOS provided desired product **2.26** in 60% yield, 82:18 e.r. with 8:1 ratio of **2.26/2.27** (entry 11). A lower catalyst loading (with 6 mol % of **L11** and 5 mol % of CuCl) gave a similar result (entry 13).


Table 2.1 Ligand Screening for Cu-H Addition to Allenyl-B(pin)/Conjugate Addition




L1




L2




L3




L4




L5




L6




L7




L8



L9



L10



L11


| Entry | Ligand | Conv. % ^b | 2.26:2.27 ^c | Yield % ^d | e.r. ^e |
|-------|-----------|----------------------|------------------------|----------------------|-------------------|
| 1 | L1 | >98 | NA | <2 | NA |
| 2 | L2 | >98 | NA | <2 | NA |
| 3 | L3 | >98 | 4:1 | 52 | 55:45 |
| 4 | L4 | >98 | 4:1 | 50 | 67:33 |
| 5 | L5 | >98 | 1:1.5 | 21 | 50:50 |

| | | | | | |
|-----------------|-----------------------|-----|--------|----|-------|
| 6 | L6 | >98 | 6:1 | 58 | 61:39 |
| 7 | L7 | >98 | 6:1 | 68 | 65:35 |
| 8 | L8 | >98 | NA | <2 | NA |
| 9 | L9^f | >98 | NA | <2 | NA |
| 10 | L10 | >98 | 2:1 | 38 | 74:26 |
| 11 | L11 | >98 | 8:1 | 60 | 82:18 |
| 12 | SIMes | >98 | 1:1.5 | 29 | NA |
| 13 ^g | L11 | >98 | 6:1 | 66 | 80:20 |
| 14 | - | >98 | <2:>98 | NA | NA |

^a Reactions were performed under N₂ atmosphere. ^{b,c} Determined by analysis of 400 MHz ¹H NMR of unpurified mixtures. ^d Isolated yield of pure product. ^e Determined by HPLC analysis. ^f With 10 mol % of **L9** and CuCl. ^g With 6 mol % of **L11** and 5 mol % CuCl.

With **L11** in hand, we tried to further optimize the reaction conditions. A variety of conditions were tested, as shown in table 2.2. A screening of bases (entry 1-7) indicate that NaOPh (entry 5) can give the best result (compared with LiOMe, LiOtBu, NaOMe, NaOtBu, NaOAc and KOtBu) with 66% yield and 87:13 e.r. Reactions performed at lower temperatures are less efficient (entries 8,9 vs. 5) with lower conversion and yield, but with higher e.r. and chemoselectivity. The yield of **2.26** is further improved with a higher catalyst loading (9 mol % of **L11** and 7.5 mol % of CuCl vs of 6 mol % of **L11** and 5 mol % of CuCl) and more reagent **2.2** (3 equiv. vs. 2 equiv.), to deliver an efficient reaction with 98% conversion of starting material **2.25**, 77% yield of conjugate addition product **2.26**, 95:5 e.r. and >20:1 ratio of **2.26/2.27** (entry 11).

Table 2.2 Optimization of Reaction Conditions for Cu-H Addition to Allenyl-B(pin)/Conjugate Addition



| Entry | Base | Conv. % ^b | Temp. °C | 2.26:2.27 ^c | Yield % ^d | e.r. ^e |
|-------------------|--------|----------------------|----------|-------------------------------|----------------------|-------------------|
| 1 | LiOMe | 90 | 22 | 8:1 | 52 | 80:20 |
| 2 | LiOtBu | >98 | 22 | 6:1 | 66 | 80:20 |
| 3 | NaOMe | >98 | 22 | NA | <2 | NA |
| 4 | NaOtBu | >98 | 22 | NA | <2 | NA |
| 5 | NaOPh | >98 | 22 | 7:1 | 66 | 87:13 |
| 6 | NaOAc | <5 | 22 | NA | ND | NA |
| 7 | KOtBu | >98 | 22 | 6:1 | <2 | 65:35 |
| 8 | NaOPh | 82 | 4 | >10:1 | 58 | 90:10 |
| 9 | NaOPh | 59 | -30 | >20:1 | 42 | 94:6 |
| 10 ^f | NaOPh | 86 | -30 | >20:1 | 71 | 95:5 |
| 11 ^{f,g} | NaOPh | 98 | -30 | >20:1 | 77 | 95:5 |


^a Reactions were performed under N₂ atmosphere. ^{b,c} Determined by analysis of 400 MHz ¹H NMR of unpurified mixtures. ^d Isolated yield of pure product. ^e Determined by HPLC analysis. ^f With 9 mol % of **L11** and 7.5 mol % CuCl. ^g With 3 equiv. of **2.2**.

2.4 SCOPE OF CATALYTIC ENANTIOSELECTIVE MULTICOMPONENT ALLYL CONJUGATE ADDITION

With the optimum conditions in hand, we examined the substrate scope for the multicomponent allyl conjugate addition. As shown in scheme 2.8, halogen substituents (**2.26c-d**) are well tolerated. Sterically demanding substrate **2.26b**, although less efficient,

works well (67% yield and 92:8 e.r.). Electron deficient **2.26f** and rich (**2.26e**) substrates are suitable. Heterocycle containing substrates (**2.26h-i**) are also compatible with reaction conditions to deliver products in high efficiency (84% yield, 95:5 e.r.; 75% yield, 92:8 e.r., respectively). Cu-H addition products, as well as Z- products are not observed in any of these cases.


Scheme 2.8 Substrate Scope for Cu-H Addition to Allenyl-B(pin)/Conjugate Addition



2.5 FUNCTIONALIZATION OF PRODUCTS OF CATALYTIC ENANTIOSELECTIVE MULTICOMPONENT ALLYL CONJUGATE ADDITION


Alkenyl boronic esters are broadly useful functional motifs in organic synthesis.¹⁸ Not only they possess high chemical stability, they can also participate in a variety of transformations. In 2017, Yun and co-workers reported a Cu-catalyzed regio- and enantioselective hydroallylation of alkenyl boronates and boramides (scheme 2.9).¹⁹

Scheme 2.9 Cu-Catalyzed Enantioselective Hydroallylation of Alkenyl-B(pin)



We tested the Cu-catalyzed enantioselective hydroallylation of alkenyl boronates as reported above (scheme 2.10). Under the reported conditions, we observed low conversion of alkenyl-B(pin) **2.26** (30~40%), and recovered non-separable mixture.

Scheme 2.10 Functionalization of Alkenyl-B(pin)



- (18) (a) Ramachandran, P. V.; Brown, H. C. Recent Advances in Borane Chemistry. In *Organoboranes for Synthesis*; ACS Symposium Series 783; American Chemical Society: Washington, DC, 2001. (b) Matteson, D. S. *Tetrahedron* **1989**, 45, 1859. (c) Brown, H. C.; Campbell, J. B., Jr. *Aldrichimica Acta* **1981**, 14, 3. (d) Hall, D. G., Ed. *Boronic Acids: Preparation, Applications in Organic Synthesis and Medicine*, 2nd ed.; Wiley-VCH: Weinheim, 2011.
- (19) J. T. Han, W. J. Jang, N. Kim, J. Yun, *J. Am. Chem. Soc.* **2016**, 138, 15146–15149.

2.6 CONCLUSION

In this chapter, we have developed a facile multicomponent catalytic process that begins with a chemo- and site-selective copper-hydride addition to allenyl-B(pin) followed by enantioselective conjugate addition of the resulting allylcopper intermediate to α,β -unsaturated malonates, generating products that contain a stereogenic center and an easily functionalizable alkenyl-B(pin) in up to 84% yield, >98:2 E/Z selectivity and 96:4 enantiomeric ratio. The transformations are catalyzed by chiral Cu complexes derived from commercially available bisphosphines. Further studies on expanding substrate scope, functionalization of products and application towards synthesis of valuable compounds are ongoing.

2.7 EXPERIMENTAL

General

Infrared (IR) spectra were recorded on a Bruker FT-IR Alpha (ATR mode) spectrophotometer, ν_{max} in cm^{-1} . Bands are characterized as broad (br), strong (s), medium (m), and weak (w). ^1H NMR spectra were recorded on a Varian Unity INOVA 400 (400 MHz) spectrometer. Chemical shifts are reported in ppm from tetramethylsilane with the solvent resonance as the internal standard (CDCl_3 : δ 7.26 ppm). Data are reported as follows: chemical shift, integration, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br s = broad singlet, m = multiplet, app. = apparent), and coupling constant (Hz). ^{13}C NMR spectra were recorded on a Varian Unity INOVA 400 (100 MHz)

spectrometer with complete proton decoupling. Chemical shifts are reported in ppm from tetramethylsilane with the solvent resonance as the internal standard (CDCl_3 : δ 77.00 ppm). High-resolution mass spectrometry was performed on a JEOL AccuTOF DART (positive mode) at the Mass Spectrometry Facility, Boston College. Enantiomer ratios were determined by high-performance liquid chromatography (HPLC) with a Shimadzu chromatograph (Chiral Technologies Chiralpak AZ-H (5.0×250 mm), Chiralpak OD-H (5.0×250 mm)) in comparison with authentic racemic materials. Specific rotations were measured on a Rudolph Research Analytical Autopol IV polarimeter.

Unless otherwise noted, all reactions were carried out with distilled and degassed solvents under an atmosphere of dry N_2 in oven- (135°C) or flame-dried glassware with standard dry box or vacuum-line techniques. Solvents were purified under a positive pressure of dry argon by a modified Innovative Technologies purification system: toluene, benzene and hexanes were purified through a copper oxide and alumina column; CH_2Cl_2 and Et_2O were purged with Ar and purified by passage through two alumina columns. Tetrahydrofuran (Aldrich Chemical Co.) was purified by distillation from sodium benzophenone ketyl immediately prior to use unless otherwise specified. All work-up and purification procedures were carried out with reagent grade solvents (purchased from Fisher Scientific) in air.

Reagents and Ligands

Allenylboronic acid pinacol ester (2.2): purchased from Aldrich Chemical Co. and used as received.

Copper (I) chloride: purchased from Strem Chemicals Inc. and used as received.

Diethyl allyl phosphate (2.29): purchased from Aldrich Chemical Co. and used as received.

Diethyl benzylidenemalonate (2.25): purchased from Aldrich Chemical Co. and used as received.

Enoate (2.25b-i): prepared according to previously reported procedures.²⁰

L1-L11: purchased from Strem Chemicals Inc. and used as received.

Lithium *tert*-butoxide: purchased from Strem Chemicals Inc. and used as received.

Lithium methoxide: purchased from Strem Chemicals Inc. and used as received.

Poly(methylhydrosiloxane): purchased from Aldrich Chemical Co. and used as received.

Potassium *tert*-butoxide: purchased from Strem Chemicals Inc. and used as received.

SIMes chloride: purchased from Aldrich Chemical Co. and used as received.

Sodium *tert*-butoxide: purchased from Strem Chemicals Inc. and used as received.

Sodium methoxide: purchased from Strem Chemicals Inc. and used as received.

Sodium phenoxide: purchased from Strem Chemicals Inc. and used as received.

Representative Procedure for Multicomponent Allyl Conjugate Addition:



An oven-dried 1 dram vial equipped with a stir bar was weighed and charged with phosphine **L11** (10.6 mg, 9 μ mol), CuCl (0.75 mg, 7.5 μ mol) and NaOPh (14.4 mg, 150 μ mol) in a N₂-filled glove box. Freshly distilled THF (1.0 mL) was added to the vial and the mixture was allowed to stir at 22 °C for 0.5 h. After that, PMHS (18.0 mg, 0.3 mmol) and allenyl-B(pin) **2.2** (49.8 mg, 0.3 mmol) was added into the vial. The vial was sealed with a cap (phenolic open top cap with a red PTFE/white silicon septum) and electrical tape, removed from the glove box, and cooled down to -78 °C before malonate (24.8 mg,

(20) C. F. H. Allen, F. W. Spangler, *Org. Syn.* **1945**, 25, 42.

0.10 mmol) was added by a syringe. The vial was then moved into the cryocool and kept at -30 °C for 24 h. After that, the mixture was passed through a short plug of silica gel and eluted with Et₂O. The organic layer was concentrated *in vacuo* and purified by silica gel chromatography to afford the desired product as colorless oil.

Diethyl (*E*)-2-(1-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)but-3-en-1-yl)malonate (2.26):

IR (neat): 2979 (m), 1732 (s), 1638 (m), 1365 (s), 1321 (m), 1250 (m), 1144 (s), 850 (w), 701 (m) cm⁻¹; ¹H NMR (CDCl₃, 400 MHz): δ 7.27-7.15 (5H, m), 6.37 (1H, dt, *J* = 17.6, 6.8 Hz), 5.34 (1H, dd, *J* = 18.0, 1.6 Hz), 4.19 (2H, q, *J* = 7.2 Hz), 3.88 (2H, q, *J* = 7.2 Hz), 3.66 (1H, d, *J* = 10.4 Hz), 3.57-3.51 (1H, m), 2.59-2.55 (1H, m), 1.26 (3H, t, *J* = 7.2 Hz), 1.20 (12H, s), 0.95 (3H, t, *J* = 7.2 Hz); ¹³C NMR (CDCl₃, 100 MHz): δ 168.2, 167.7, 150.2, 140.4, 128.3, 128.2, 126.9, 83.0, 61.5, 61.1, 58.0, 44.7, 40.4, 24.7, 24.7, 14.0, 13.7; HRMS (ESI⁺): Calcd for C₂₃H₃₄BO₆ [M+H]⁺: 417.2448; Found: 417.2455. Specific rotation: [α]_D²⁰ 17.3 (c 1.5, CHCl₃) for an enantiomerically enriched sample of 95:5 e.r. Enantiomeric purity was determined by HPLC analysis in comparison with authentic racemic material; Chiralpak AZ-H column, 98.0:2.0 hexanes/*i*PrOH, 1.0 mL/min, 220 nm.




| Peak # | Time (min) | Area (%) | Peak # | Time (min) | Area (%) |
|--------|------------|----------|--------|------------|----------|
| 1 | 14.910 | 49.800 | 1 | 16.065 | 5.212 |
| 2 | 18.564 | 50.200 | 2 | 19.667 | 94.788 |

Diethyl (*E*)-2-(1-(2-methoxyphenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)but-3-en-1-yl)malonate (2.26b):

IR (neat): 2979 (m), 1732 (s), 1637 (m), 1493 (m), 1365 (s), 1320 (m), 1244 (s), 1144 (s), 1030 (m), 849 (w), 754 (m) cm^{-1} ; ^1H NMR (CDCl_3 , 400 MHz): δ 7.18-7.02 (2H, m), 6.85-6.81 (2H, m), 6.41 (1H, dt, $J = 10.8, 6.8$ Hz), 5.31 (1H, d, $J = 18.0$ Hz), 4.18 (2H, q, $J = 7.2$ Hz), 3.99 (1H, d, $J = 14.4$ Hz), 3.94-3.82 (6H, m), 2.73-2.66 (1H, m), 2.57-2.51 (1H, m), 1.27 (3H, t, $J = 7.2$ Hz), 1.20 (12H, s), 0.96 (3H, t, $J = 7.6$ Hz); ^{13}C NMR (CDCl_3 , 100 MHz): δ 168.6, 168.2, 157.6, 151.4, 129.8, 128.3, 127.9, 120.2, 110.7, 82.9, 61.3, 60.9, 55.8, 55.2, 38.5, 24.7, 14.1, 13.7; HRMS (ESI^+): Calcd for $\text{C}_{24}\text{H}_{36}\text{BO}_7$ $[\text{M}+\text{H}]^+$: 447.2554; Found: 447.255. Specific rotation: $[\alpha]_{\text{D}}^{20} -4.9$ (c 1.5, CHCl_3) for an enantiomerically enriched sample of 92:8 e.r.


Enantiomeric purity was determined by HPLC analysis in comparison with authentic racemic material; Chiralpak AZ-H column, 98.0:2.0 hexanes/*i*PrOH, 1.0 mL/min, 220 nm.



<Peak Table>

Detector A Channel 2 220nm

| Peak# | Ret. Time | Area | Height | Conc. | Unit | Mark |
|-------|-----------|---------|--------|--------|------|------|
| 1 | 13.954 | 4676515 | 209464 | 50.660 | | M |
| 2 | 14.810 | 4554717 | 178229 | 49.340 | | M |
| Total | | 9231232 | 387693 | | | |



<Peak Table>

Detector A Channel 2 220nm


| Peak# | Ret. Time | Area | Height | Conc. | Unit | Mark |
|-------|-----------|----------|--------|--------|------|------|
| 1 | 13.612 | 863766 | 43755 | 7.826 | | M |
| 2 | 14.398 | 10173910 | 395196 | 92.174 | | M |
| Total | | 11037676 | 438950 | | | |

| Peak # | Time (min) | Area (%) | Peak # | Time (min) | Area (%) |
|--------|------------|----------|--------|------------|----------|
| 1 | 13.954 | 50.660 | 1 | 13.612 | 7.826 |
| 2 | 14.810 | 49.340 | 2 | 14.398 | 92.174 |

Diethyl (*E*)-2-(1-(3-bromophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)but-3-en-1-yl)malonate (2.26c):

IR (neat): 2979 (m), 1732 (s), 1638 (m), 1365 (s), 1322 (m), 1249 (m), 1144 (s), 849 (w), 697 (w) cm^{-1} ; ^1H NMR (CDCl_3 , 400 MHz): δ 7.34-7.31 (2H, m), 7.15-7.13 (2H, m), 6.34 (1H, dt, J = 18.0, 7.2 Hz), 5.35 (1H, d, J = 17.6 Hz), 4.23-4.18 (2H, m), 3.93 (2H, q, J = 7.2 Hz), 3.63 (1H, d, J = 10.4 Hz), 3.54-3.48 (1H, m), 2.59-2.49 (2H, m), 1.28 (3H, t, J = 7.2 Hz), 1.20 (12H, s), 1.00 (3H, t, J = 7.2 Hz); ^{13}C NMR (CDCl_3 , 100 MHz): δ 167.8, 167.4, 149.5, 142.8, 131.4, 130.1, 129.8, 127.0, 122.3, 83.1, 61.6, 61.3, 57.7, 44.3, 40.1, 24.7, 14.0, 13.7; HRMS (ESI^+): Calcd for $\text{C}_{23}\text{H}_{33}\text{BBrO}_6$ $[\text{M}+\text{H}]^+$: 495.1554; Found: 495.1567. Specific rotation: $[\alpha]_{\text{D}}^{20}$ 1.4 (c 2.0, CHCl_3) for an enantiomerically enriched sample of 91:9 e.r.


Enantiomeric purity was determined by HPLC analysis in comparison with authentic racemic material; Chiralpak AZ-H column, 98.0:2.0 hexanes/*i*PrOH, 1.0 mL/min, 220 nm.



<Peak Table>

Detector A Channel 2 220nm

| Peak# | Ret. Time | Area | Height | Conc. | Unit | Mark |
|-------|-----------|----------|--------|--------|------|------|
| 1 | 15.535 | 17633935 | 586052 | 51.317 | | M |
| 2 | 17.464 | 16728949 | 328411 | 48.683 | | M |
| Total | | 34362884 | 914464 | | | |



<Peak Table>

Detector A Channel 2 220nm


| Peak# | Ret. Time | Area | Height | Conc. | Unit | Mark |
|-------|-----------|----------|--------|--------|------|------|
| 1 | 15.183 | 2412825 | 87568 | 8.976 | | M |
| 2 | 16.961 | 24468258 | 496443 | 91.024 | | M |
| Total | | 26881083 | 584011 | | | |

| Peak # | Time (min) | Area (%) | Peak # | Time (min) | Area (%) |
|--------|------------|----------|--------|------------|----------|
| 1 | 15.535 | 51.317 | 1 | 15.183 | 8.976 |
| 2 | 17.464 | 48.683 | 2 | 16.961 | 91.024 |

Diethyl (*E*)-2-(1-(4-fluorophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)but-3-en-1-yl)malonate (2.26d):


IR (neat): 2980 (m), 1731 (s), 1638 (m), 1510 (m), 1364 (s), 1320 (s), 1225 (s), 1143 (s), 1033 (m), 839 (m) cm^{-1} ; ^1H NMR (CDCl_3 , 400 MHz): δ 7.18-7.13 (2H, m), 6.98-6.92 (2H, m), 6.34 (1H, dt, $J = 18.0, 7.2$ Hz), 5.34 (1H, d, $J = 18.0$ Hz), 4.20 (2H, q, $J = 7.2$ Hz), 3.93-3.88 (2H, m), 3.62 (1H, d, $J = 12.4$ Hz), 3.56-3.50 (1H, m), 2.61-2.46 (2H, m), 1.27 (3H, t, $J = 7.2$ Hz), 1.21 (12H, s), 1.00 (3H, t, $J = 7.2$ Hz); ^{13}C NMR (CDCl_3 , 100 MHz): δ 168.0, 167.6, 161.7 (d, $J = 244$ Hz), 149.8, 136.0 (d, $J = 3$ Hz), 129.8 (d, $J = 8$ Hz), 115.1 (d, $J = 21$ Hz), 83.0, 61.6, 61.2, 58.0, 43.9, 40.4, 24.7, 14.0, 13.7; HRMS (ESI^+): Calcd for $\text{C}_{23}\text{H}_{33}\text{BFO}_6$ $[\text{M}+\text{H}]^+$: 435.2354; Found: 435.2347.

Enantiomeric purity was determined by HPLC analysis in comparison with authentic racemic material; Chiralpak AZ-H column, 98.0:2.0 hexanes/*i*PrOH, 1.0 mL/min, 220 nm.



<Peak Table>

| Peak# | Ret. Time | Area | Height | Conc. | Unit | Mark |
|-------|-----------|---------|--------|--------|------|------|
| 1 | 15.659 | 2774854 | 94842 | 50.945 | | M |
| 2 | 18.193 | 2671887 | 53419 | 49.055 | | M |
| Total | | 5446741 | 148262 | | | |



<Peak Table>



| Peak# | Ret. Time | Area | Height | Conc. | Unit | Mark |
|-------|-----------|---------|--------|--------|------|------|
| 1 | 15.220 | 293259 | 10400 | 6.309 | | M |
| 2 | 17.610 | 4355134 | 91027 | 93.691 | | M |
| Total | | 4648393 | 101427 | | | |

| Peak # | Time (min) | Area (%) | Peak # | Time (min) | Area (%) |
|--------|------------|----------|--------|------------|----------|
| 1 | 15.659 | 50.945 | 1 | 15.220 | 6.309 |
| 2 | 18.193 | 49.055 | 2 | 17.610 | 93.691 |

Diethyl (*E*)-2-(1-(4-methoxyphenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)but-3-en-1-yl)malonate (2.26e):

^1H NMR (CDCl_3 , 400 MHz): δ 7.11-7.10 (2H, m), 6.81-6.78 (2H, m), 6.37 (1H, dt, J = 18.0, 6.8 Hz), 5.35 (1H, d, J = 18.0 Hz), 4.20 (2H, q, J = 7.2 Hz), 3.90 (2H, q, J = 7.2 Hz), 3.76 (3H, s), 3.61 (1H, d, J = 10.4 Hz), 3.52-3.46 (1H, m), 2.55-2.51 (2H, m), 1.27 (3H, t, J = 7.6 Hz), 1.20 (12H, s), 0.98 (3H, t, J = 7.2 Hz); ^{13}C NMR (CDCl_3 , 100 MHz): δ 168.2, 167.7, 158.4, 150.4, 132.4, 129.3, 113.6, 83.0, 61.4, 61.1, 58.2, 55.1, 43.9, 40.5, 24.7, 14.1, 13.8.

Enantiomeric purity was determined by HPLC analysis in comparison with authentic racemic material; Chiralpak AZ-H column, 94.0:6.0 hexanes/*i*PrOH, 1.0 mL/min, 220 nm.




| Peak # | Time (min) | Area (%) | Peak # | Time (min) | Area (%) |
|--------|------------|----------|--------|------------|----------|
| 1 | 17.375 | 50.794 | 1 | 17.044 | 4.185 |
| 2 | 20.395 | 49.206 | 2 | 19.872 | 95.815 |

Diethyl (*E*)-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(4-

(trifluoromethyl)phenyl)but-3-en-1-yl)malonate (2.26f):


IR (neat): 2980 (w), 1733 (m), 1638 (w), 1364 (m), 1324 (s), 1143 (s), 1069 (s), 848 (w) cm^{-1} ; ^1H NMR (CDCl_3 , 400 MHz): δ 7.53 (2H, d, $J = 8.0$ Hz), 7.32 (2H, d, $J = 8.0$ Hz), 6.31 (1H, dt, $J = 18.0, 6.8$ Hz), 5.35 (1H, d, $J = 17.6$ Hz), 4.24-4.19 (2H, m), 3.93-3.87 (2H, m), 3.69-3.59 (2H, m), 2.63-2.52 (2H, m), 1.30-1.23 (3H, m), 1.21 (12H, s), 0.96 (3H, t, $J = 7.2$ Hz); ^{13}C NMR (CDCl_3 , 100 MHz): δ 167.8, 167.4, 149.2, 144.6, 129.1 (q, $J = 29$ Hz), 128.7, 125.5-125.2 (m), 122.8, 83.1, 61.7, 61.3, 57.5, 40.0, 24.7, 24.7, 14.0, 13.6.

Enantiomeric purity was determined by HPLC analysis in comparison with authentic racemic material; Chiralpak OD-H column, 98.0:2.0 hexanes/*i*PrOH, 1.0 mL/min, 220 nm.



<Peak Table>

| Peak# | Ret. Time | Area | Height | Conc. | Unit | Mark |
|-------|-----------|----------|---------|--------|------|------|
| 1 | 6.411 | 9024297 | 779118 | 49.635 | | M |
| 2 | 6.870 | 9157073 | 697917 | 50.365 | | V M |
| Total | | 18181370 | 1477035 | | | |



<Peak Table>


| Peak# | Ret. Time | Area | Height | Conc. | Unit | Mark |
|-------|-----------|----------|---------|--------|------|------|
| 1 | 6.324 | 2311459 | 220882 | 9.257 | | M |
| 2 | 6.720 | 22659361 | 1805236 | 90.743 | | V M |
| Total | | 24970819 | 2026118 | | | |

| Peak # | Time (min) | Area (%) | Peak # | Time (min) | Area (%) |
|--------|------------|----------|--------|------------|----------|
| 1 | 6.411 | 49.635 | 1 | 6.324 | 9.257 |
| 2 | 6.870 | 50.365 | 2 | 6.720 | 90.743 |

Diethyl (*E*)-2-(1-(naphthalen-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)but-3-en-1-yl)malonate (2.26g):


IR (neat): 2978 (m), 1731 (s), 1637 (m), 1362 (s), 1320 (s), 1143 (s), 1031 (m), 849 (m), 748 (m), 479 (m) cm^{-1} . ^1H NMR (CDCl_3 , 400 MHz): δ 7.80-7.75 (3H, m), 7.65 (1H, s), 7.45-7.40 (2H, m), 7.37-7.34 (1H, m), 6.40 (1H, dt, $J = 17.6, 6.8$ Hz), 5.38 (1H, d, $J = 18.0$ Hz), 4.23 (2H, q, $J = 7.2$ Hz), 3.88-3.70 (4H, m), 2.69-2.66 (2H, m), 1.30-1.26 (3H, m), 1.18 (12H, s), 0.86 (3H, t, $J = 7.2$ Hz); ^{13}C NMR (CDCl_3 , 100 MHz): δ 168.2, 167.7, 150.1, 137.9, 133.3, 132.6, 128.0, 127.8, 127.5, 127.3, 126.3, 125.9, 125.6, 83.0, 61.6, 61.2, 58.1, 44.8, 40.3, 24.7, 14.1, 13.6.

Enantiomeric purity was determined by HPLC analysis in comparison with authentic racemic material; Chiralpak AZ-H column, 98.0:2.0 hexanes/*i*PrOH, 1.0 mL/min, 220 nm.



<Peak Table>

| Detector A Channel 2 220nm | | | | | | |
|----------------------------|-----------|----------|--------|--------|------|------|
| Peak# | Ret. Time | Area | Height | Conc. | Unit | Mark |
| 1 | 30.861 | 10662153 | 172976 | 51.851 | | M |
| 2 | 38.114 | 9900994 | 66014 | 48.149 | | M |
| Total | | 20563147 | 238990 | | | |




<Peak Table>

| Detector A Channel 2 220nm | | | | | | |
|----------------------------|-----------|----------|--------|--------|------|------|
| Peak# | Ret. Time | Area | Height | Conc. | Unit | Mark |
| 1 | 30.148 | 1757721 | 29846 | 4.822 | | M |
| 2 | 37.127 | 34696202 | 253425 | 95.178 | | M |
| Total | | 36453924 | 283271 | | | |

| Peak # | Time (min) | Area (%) | Peak # | Time (min) | Area (%) |
|--------|------------|----------|--------|------------|----------|
| 1 | 30.861 | 51.851 | 1 | 30.148 | 4.822 |
| 2 | 38.114 | 48.149 | 2 | 37.127 | 95.178 |

Diethyl (*E*)-2-(1-(benzofuran-5-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)but-3-en-1-yl)malonate (2.26h):


^1H NMR (CDCl_3 , 400 MHz): δ 7.58 (1H, d, $J = 0.4$ Hz), 7.43 (1H, d, $J = 1.6$ Hz), 7.39 (1H, d, $J = 8.4$ Hz), 7.13 (1H, dd, $J = 8.8, 1.6$ Hz), 6.70 (1H, dd, $J = 2.4, 0.8$ Hz), 6.38 (1H, dt, $J = 18.0, 6.8$ Hz), 5.36 (1H, d, $J = 18.0$ Hz), 4.21 (2H, q, $J = 6.8$ Hz), 3.88-3.83 (2H, m), 3.71-3.61 (2H, m), 2.61-2.59 (2H, m), 1.27 (3H, t, $J = 6.8$ Hz), 1.19 (12H, s), 0.90 (3H, t, $J = 7.2$ Hz); ^{13}C NMR (CDCl_3 , 100 MHz): δ 168.2, 167.7, 154.0, 150.3, 145.1, 134.9, 127.4, 124.7, 120.9, 111.0, 106.6, 83.0, 61.5, 61.1, 58.5, 44.6, 40.8, 24.7, 14.1, 13.7; HRMS (ESI^+): Calcd for $\text{C}_{25}\text{H}_{37}\text{BO}_7\text{N}$: 474.2663; Found: 474.2674. Specific rotation: $[\alpha]_{\text{D}}^{20} -8.3$ (c 2.0, CHCl_3) for an enantiomerically enriched sample of 95:5 e.r. Enantiomeric purity was determined by HPLC analysis in comparison with authentic racemic material; Chiralpak AZ-H column, 98.0:2.0 hexanes/*i*PrOH, 1.0 mL/min, 220 nm.



<Peak Table>

Detector A Channel 2 220nm

| Peak# | Ret. Time | Area | Height | Conc. | Unit | Mark |
|-------|-----------|----------|--------|--------|------|------|
| 1 | 33.478 | 6747835 | 96984 | 50.647 | | M |
| 2 | 39.565 | 6575350 | 55517 | 49.353 | | M |
| Total | | 13323185 | 152501 | | | |



<Peak Table>

Detector A Channel 2 220nm

| Peak# | Ret. Time | Area | Height | Conc. | Unit | Mark |
|-------|-----------|----------|--------|--------|------|------|
| 1 | 32.476 | 1028449 | 14548 | 4.977 | | M |
| 2 | 38.203 | 19637120 | 170395 | 95.023 | | M |
| Total | | 20665569 | 184943 | | | |

| Peak # | Time (min) | Area (%) | Peak # | Time (min) | Area (%) |
|--------|------------|----------|--------|------------|----------|
| 1 | 33.478 | 50.647 | 1 | 32.476 | 4.977 |
| 2 | 39.565 | 49.353 | 2 | 38.203 | 95.023 |

Diethyl (*E*)-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(thiophen-3-yl)but-3-en-1-yl)malonate (2.26i):

IR (neat): 2979 (m), 1732 (s), 1638 (m), 1363 (s), 1321 (s), 1144 (s), 849 (m) cm^{-1} . ^1H

NMR (CDCl_3 , 400 MHz): δ 7.20-7.18 (1H, m), 7.01-7.00 (1H, m), 6.94 (1H, d, $J = 4.8$ Hz), 6.40 (1H, dt, $J = 18.0, 6.8$ Hz), 5.37 (1H, dd, $J = 18.0, 1.6$ Hz), 4.17 (2H, q, $J = 7.2$ Hz), 3.94 (2H, q, $J = 6.8$ Hz), 3.72-3.66 (1H, m), 3.60 (1H, d, $J = 9.6$ Hz), 2.57-2.52

(2H, m), 1.25 (3H, t, $J = 6.8$ Hz), 1.20 (12H, s), 1.02 (3H, t, $J = 7.2$ Hz); ^{13}C NMR

(CDCl_3 , 100 MHz): δ 168.1, 167.8, 150.2, 141.1, 127.2, 125.2, 122.1, 83.0, 61.5, 61.2,

57.7, 40.2, 39.9, 24.7, 24.7, 14.0, 13.8; HRMS (ESI^+): Calcd for $\text{C}_{21}\text{H}_{32}\text{BO}_6\text{S}$ $[\text{M}+\text{H}]^+$:


423.2013; Found: 423.2026. Specific rotation: $[\alpha]_{\text{D}}^{20}$ 8.3 (c 1.0, CHCl_3) for an

enantiomerically enriched sample of 92:8 e.r.

Enantiomeric purity was determined by HPLC analysis in comparison with authentic

racemic material; Chiralpak AZ-H column, 98.0:2.0 hexanes/*i*PrOH, 1.0 mL/min, 220


nm.



<Peak Table>

Detector A Channel 2 220nm

| Peak# | Ret. Time | Area | Height | Conc. | Unit | Mark |
|-------|-----------|---------|--------|--------|------|------|
| 1 | 20.530 | 4777526 | 106797 | 50.860 | | M |
| 2 | 25.964 | 4615893 | 53407 | 49.140 | | M |
| Total | | 9393419 | 160204 | | | |




<Peak Table>


Detector A Channel 2 220nm



| Peak# | Ret. Time | Area | Height | Conc. | Unit | Mark |
|-------|-----------|----------|--------|--------|------|------|
| 1 | 20.189 | 1054293 | 24057 | 7.996 | | M |
| 2 | 25.140 | 12130352 | 146770 | 92.004 | | M |
| Total | | 13184645 | 170827 | | | |



| Peak # | Time (min) | Area (%) | Peak # | Time (min) | Area (%) |
|--------|------------|----------|--------|------------|----------|
| 1 | 20.530 | 50.860 | 1 | 20.189 | 7.996 |
| 2 | 25.964 | 49.140 | 2 | 25.140 | 92.004 |







2.26
































Pulse Sequence: **CARBON (zgpg3)**
 Solvent: **cdcl3**
 Data collected on: **Nov 23 2016**







Zy-2-289-2p-13C



| | | | | | | | |
|----------------|-----------------|----------------|--------|--------------|---------------|-------------|-------|
| Sample Name | Zy-2-289-2p-13C | Pulse sequence | CARBON | Temperature | 25 | Study owner | mengf |
| Date collected | 2016-10-16 | Solvent | cdcl3 | Spectrometer | nmr13-vnmr400 | Operator | mengf |









2.26g










Zy-2-297-4p

Sample Name Zy-2-297-4p
Date collected 2016-11-22

Pulse sequence PROTON
Solvent cdcl3

Temperature 25
Spectrometer nm13-vnmrs400

Study owner mengf
Operator mengf



2.261

